SAREPTA THERAPEUTICS, INC. Increase (Decrease) in Accounts Payable and Accrued Liabilities
SAREPTA THERAPEUTICS, INC. (SRPT) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of -$3.13 million for the 9-month period ending 2015-09-30, per its 10-Q filed 2015-11-05.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2015-11-05
- SAREPTA THERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2015-09-30 was -$2.56M.
- SAREPTA THERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2015-06-30 was $4.52M.
- SAREPTA THERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2015-03-31 was -$5.08M, a 398.36% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2014-12-31 was $15.27M, a 100.88% increase year-over-year.
- SAREPTA THERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2014 was $10.76M, a 13.68% increase from fiscal 2013.
- SAREPTA THERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2013 was $9.47M.
- SAREPTA THERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2012 was -$1.72M.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 404 month |
|---|---|---|---|---|---|
| 2015-09-30 | -$2.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | $1.96M derived: sum of 2 quarters · filed 2015-11-05 | -$3.13M 10-Q · filed 2015-11-05 | $12.14M derived: sum of 4 quarters · filed 2015-11-05 | |
| 2015-06-30 | $4.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | -$566.00K 10-Q · filed 2015-08-06 | $14.70M derived: sum of 3 quarters · filed 2015-08-06 | $14.49M derived: sum of 4 quarters · filed 2015-11-05 | |
| 2015-03-31 | -$5.08M 10-Q · filed 2015-05-07 | $10.19M derived: sum of 2 quarters · filed 2015-05-07 | $9.97M derived: sum of 3 quarters · filed 2015-11-05 | $3.98M derived: sum of 4 quarters · filed 2015-11-05 | |
| 2014-12-31 | $15.27M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-26 | $15.05M derived: sum of 2 quarters · filed 2015-11-05 | $9.06M derived: sum of 3 quarters · filed 2015-11-05 | $10.76M 10-K · filed 2015-02-26 | |
| 2014-09-30 | -$215.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | -$6.21M derived: sum of 2 quarters · filed 2015-11-05 | -$4.51M 10-Q · filed 2015-11-05 | $3.10M derived: sum of 4 quarters · filed 2015-11-05 | |
| 2014-06-30 | -$6.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | -$4.29M 10-Q · filed 2015-08-06 | $3.31M derived: sum of 3 quarters · filed 2015-08-06 | $5.47M derived: sum of 4 quarters · filed 2015-08-06 | |
| 2014-03-31 | $1.70M 10-Q · filed 2015-05-07 | $9.30M derived: sum of 2 quarters · filed 2015-05-07 | $11.47M derived: sum of 3 quarters · filed 2015-05-07 | $12.13M derived: sum of 4 quarters · filed 2015-05-07 | $23.59M 10-Q · filed 2014-05-08 |
| 2013-12-31 | $7.60M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-26 | $9.76M derived: sum of 2 quarters · filed 2015-02-26 | $10.42M derived: sum of 3 quarters · filed 2015-02-26 | $9.47M 10-K · filed 2015-02-26 | |
| 2013-09-30 | $2.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | $2.82M derived: sum of 2 quarters · filed 2014-11-06 | $1.87M 10-Q · filed 2014-11-06 | ||
| 2013-06-30 | $661.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | -$294.00K 10-Q · filed 2014-08-07 | |||
| 2013-03-31 | -$955.00K 10-Q · filed 2014-05-08 | ||||
| 2012-12-31 | -$1.72M 10-K · filed 2015-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |